癌症是一个严重的健康问题，其中癌症死亡率（癌症死亡率）为每年每10万男性和女性158.3人次（基于2013-2017年死亡数据）。临床和翻译研究均表明，慢性炎症与癌症进展有关。然而，炎性小体的精确机制和介导这一现象的途径尚未完全确定。最近确定的一个信号通路之一是“炎性小体”，它是由NLRP3（核结合域和富含亮氨酸重复蛋白3）、ASC（细胞凋亡相关斑点样蛋白）和前半胱天冬氨酸蛋白酶-1组成的多蛋白复合物。NLRP3炎症小体的激活导致前炎性细胞因子白细胞介素-1β（IL-1β）和IL-18的加工和分泌。本文的目标是回顾NLRP3炎性小体激活对不同器官之间复杂相互作用机制中的影响的新见解，以更好地理解慢性炎症在癌症发病机制中的作用。我们将在此提供对NLRP3炎性小体的当前研究的展望，这可能代表一种创新的治疗靶点，逆转由炎症造成的恶性病情后果。视频摘要。© 2023. BioMed Central Ltd., 由Springer Nature的一部分。

The cancer is a serious health problem, which is The cancer death rate (cancer mortality) is 158.3 per 100,000 men and women per year (based on 2013-2017 deaths). Both clinical and translational studies have demonstrated that chronic inflammation is associated with Cancer progression. However, the precise mechanisms of inflammasome, and the pathways that mediate this phenomenon are not fully characterized. One of the most recently identified signaling pathways, whose activation seems to affect many metabolic disorders, is the "inflammasome" a multiprotein complex composed of NLRP3 (nucleotide-binding domain and leucine-rich repeat protein 3), ASC (apoptosis associated speck-like protein containing a CARD), and procaspase-1. NLRP3 inflammasome activation leads to the processing and secretion of the proinflammatory cytokines interleukin-1β (IL-1β) and IL-18. The goal of this paper is to review new insights on the effects of the NLRP3 inflammasome activation in the complex mechanisms of crosstalk between different organs, for a better understanding of the role of chronic inflammation in cancer pathogenesis. We will provide here a perspective on the current research on NLRP3 inflammasome, which may represent an innovative therapeutic target to reverse the malignancy condition consequences of the inflammation. Video Abstract.© 2023. BioMed Central Ltd., part of Springer Nature.